What Do Most Favored Nation (MFN) Policies Mean for Pharma Market Research and Global Drug Pricing?

Executive Summary: Most Favored Nation (MFN) policies are reshaping the drug pricing landscape, and this blog post examines what that means for pharma market research, from expanding global perspectives to informing pipeline and pricing strategy, and the new questions insight leaders must be ready to answer.

You may have heard the term “Most Favored Nation” (MFN) pop up in conversations about drug pricing. If it sounds abstract or policy-heavy to you, you’re not alone. At its core, MFN is a relatively simple idea, and it has very real implications for how pharmaceutical market research teams do their jobs.

First: What Is MFN?

A Most Favored Nation policy basically says:

The U.S. shouldn’t pay more for a drug than other similar countries do.

Under an MFN approach, the price paid in the U.S. (often through Medicare) could be linked to the lowest prices paid in other countries. The goal is to reduce U.S. drug spending by preventing big price gaps between the U.S. and the rest of the world.

Whether MFN policies are fully implemented or not, the idea alone may change how pharma companies think about drug pricing. It is key to continue to keep these potential changes in mind, along with the uncertainty associated with them.

“MFN policies don’t just adjust drug pricing. They redefine the reference point for value, forcing pharma organizations to think globally about decisions that were once made in isolation.” —Courtney Kerwin, Vice President, Health & Life Sciences

It is important to recognize that current MFN policies are being implemented via Executive Order. As a result, the framework remains subject to change, and its long-term structure is far from settled, particularly given limited signals that Congress will codify it in its current form. For stakeholders across the pharmaceutical ecosystem, this introduces uncertainty that extends beyond pricing strategy into how insights are generated and applied. Market research teams will need to prioritize flexibility in study design, ensuring approaches can adapt as policy details evolve. We will continue to monitor changes in the MFN landscape and revisit these implications as new developments emerge.

Why Do MFN Policies Matter for Pharma Market Research Teams?

Because MFN changes the rules of the game for pricing, access and value perception.

For a long time, pharma companies have treated the U.S. as a separate, premium market. Market research often focused on:

• What U.S. doctors, payers and patients think
• What the U.S. market is willing to pay
• How to position products primarily for U.S. needs

MFN challenges that separation. If U.S. prices are tied to global prices, then what happens outside the U.S. suddenly matters a lot more. That shift, combined with an evolving policy landscape, means research can’t be static; it needs to be built to adapt.

What Are the Day-to-Day Implications of MFN Policies for Pharma Researchers?

1. U.S. Market Research Needs a Global Perspective

If U.S. prices depend on prices elsewhere, market research can’t just ask:

“What will U.S. stakeholders accept?”

It also needs to consider:

• How prices and access work in other countries
• How global pricing decisions ripple back into the U.S.
• Whether U.S. expectations still hold if prices are capped

That means more global thinking, even for teams focused on the U.S.

2. Scenario-Based Research Is Critical Under MFN Policies

MFN policies aren’t always clear-cut. They might apply:

• Only to certain drugs
• Only to Medicare
• Only in specific situations

So instead of asking for one clear answer, leadership will want help with questions like:

• What happens if MFN applies to our category?
• How would doctors or payers react if prices were lower or more restricted?
• What changes if access tightens?

Market research teams will be asked to run more scenario-based research, including pricing scenario modeling, policy impact forecasting and “what-if” simulations tied to MFN drug pricing rules, not just reporting what’s happening today.

“In an MFN-driven environment, the most valuable pharma research doesn’t describe what is. It anticipates what could be, helping leaders navigate uncertainty with confidence.” —Courtney Kerwin, Vice President, Health & Life Sciences 

3. Emphasizing Drug Value Matters More as Pricing Options Narrow

If you can’t rely on premium pricing, you have to rely more on clear, compelling value.

That puts pressure on market research to uncover:

• What parts of a drug’s benefit really matter to stakeholders
• Which outcomes feel “worth it” even when budgets are tight
• Where the product truly stands out from competitors

In short, research needs to help teams explain why a drug is valuable, not just how much it costs and whether patients will have coverage and access.

4. Market Researchers Must Pay Attention to Payers and Policymakers

MFN brings payers and policymakers closer to the center of decision-making.

Market research teams may need to:

• Spend more time with payer and access audiences
• Understand how policy thinking influences coverage decisions
• Track shifts in sentiment before formal policy changes

This can feel unfamiliar for teams used to focusing mostly on clinicians or patients, but it’s becoming increasingly important. It represents a meaningful expansion of traditional research audiences.

5. Consider MFN Policies in Early Drug Pipeline and Portfolio Decisions

MFN doesn’t just affect products on the market, it can influence which drugs get developed in the first place.

Research teams may be asked to help answer:

• Is this asset still attractive if pricing is more limited?
• Which therapeutic areas are more exposed to pricing pressure?
• Where does innovation still command strong value?

That pushes market research earlier in the decision process, especially for pipeline and portfolio planning.

Key Pharma Trends Market Researchers Must Track Under MFN Policies

Even if MFN policies aren’t fully rolled out yet, market research teams should keep an eye on:

• Growing sensitivity to price in stakeholder conversations
• Increased interest in global benchmarks
• More questions from leadership about policy “what ifs”
• Requests for research that integrates pricing, access and value

As shifts in MFN policies reshape both the role of market researchers and the strategic insights pharma companies must prioritize, Escalent remains at the forefront, closely tracking these developments and translating them into actionable guidance for the industry. Most recently, Escalent’s president, Christopher Barnes, delivered a keynote at Intellus Worldwide 2026 examining the political forces driving drug pricing and showing how organizations can turn these insights into informed, effective strategies. Curious how these MFN policy changes could impact your market research or business strategy? Reach out to learn more.

---

Want to learn more? Let’s connect.

---